Verici Dx plc (AIM:VRCI)
London
· Delayed Price · Currency is GBP · Price in GBX 0.5250
+0.0250 (4.76%)
Aug 15, 2025, 4:35 PM GMT+1
Verici Dx Revenue
In the year 2024, Verici Dx had annual revenue of $3.34M USD with 229.62% growth.
Revenue
$3.34M
Revenue Growth
+229.62%
P/S Ratio
2.98
Revenue / Employee
$185.50K
Employees
18
Market Cap
7.95M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
| Dec 31, 2023 | 1.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Oxford Nanopore Technologies | 183.19M |
Verici Dx News
- 3 months ago - AIM Market Roundup: Belluscura, Tiger Royalties, ITM Power - The Armchair Trader
- 4 months ago - AIM Market Roundup: Ethernity Networks, Verici DX, Aferian - The Armchair Trader
- 4 months ago - AIM Market Roundup: Rome Resources, Celadon Pharmaceuticals, Churchill China - The Armchair Trader
- 4 months ago - AIM Market Roundup: Celadon Pharma, Oracle Power, Volex - The Armchair Trader
- 9 months ago - FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians - Business Wire